Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 685,256
  • Shares Outstanding, K 124,592
  • Annual Sales, $ 144,930 K
  • Annual Income, $ -65,580 K
  • 60-Month Beta 2.69
  • Price/Sales 37.98
  • Price/Cash Flow N/A
  • Price/Book 10.45
Trade MCRB with:

Options Overview Details

View History
  • Implied Volatility 77.25% ( +0.84%)
  • Historical Volatility 46.79%
  • IV Percentile 8%
  • IV Rank 36.40%
  • IV High 154.46% on 05/11/22
  • IV Low 33.05% on 07/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 53
  • Volume Avg (30-Day) 154
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 5,292
  • Open Int (30-Day) 7,777

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.52
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +21.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.02 +9.56%
on 01/19/23
5.71 -3.68%
on 02/02/23
+0.10 (+1.85%)
since 01/03/23
3-Month
4.78 +15.18%
on 12/28/22
9.05 -39.23%
on 11/04/22
-3.49 (-38.82%)
since 11/03/22
52-Week
2.50 +120.00%
on 06/16/22
9.49 -42.04%
on 11/01/22
-1.94 (-26.08%)
since 02/03/22

Most Recent Stories

More News
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on February 1, 2023, the Compensation and Talent Committee of...

MCRB : 5.50 (-3.00%)
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of...

MCRB : 5.50 (-3.00%)
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.

MCRB : 5.50 (-3.00%)
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday,...

MCRB : 5.50 (-3.00%)
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity...

MCRB : 5.50 (-3.00%)
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 5.50 (-3.00%)
AGLE : 0.5040 (+2.86%)
Seres Therapeutics: Q3 Earnings Snapshot

Seres Therapeutics: Q3 Earnings Snapshot

MCRB : 5.50 (-3.00%)
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported third quarter 2022 financial results and provided business updates.

MCRB : 5.50 (-3.00%)
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on November 2, 2022, at 8:30 a.m....

MCRB : 5.50 (-3.00%)
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application...

MCRB : 5.50 (-3.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 5.81
2nd Resistance Point 5.71
1st Resistance Point 5.61
Last Price 5.50
1st Support Level 5.41
2nd Support Level 5.31
3rd Support Level 5.21

See More

52-Week High 9.49
Fibonacci 61.8% 6.82
Fibonacci 50% 5.99
Last Price 5.50
Fibonacci 38.2% 5.17
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar